| Literature DB >> 34852822 |
Andreas Ochs1, Johannes Riffel2,3, Marco M Ochs2,3, Nisha Arenja2,4, Thomas Fritz2, Christian Galuschky5, Andreas Schuster6, Oliver Bruder7, Heiko Mahrholdt8, Evangelos Giannitsis2,3, Norbert Frey2,3, Hugo A Katus2,3, Sebastian J Buss2,3, Florian André2,3.
Abstract
BACKGROUND: Data on the prognostic value of left ventricular (LV) morphological and functional parameters including LV rotation in patients with dilated cardiomyopathy (DCM) using cardiovascular magnetic resonance (CMR) are currently scarce. In this study, we assessed the prognostic value of global longitudinal strain (GLS), global circumferential strain (GCS), global radial strain (GRS) and LV torsion using CMR feature tracking (FT).Entities:
Keywords: Cardiac magnetic resonance; Dilated cardiomyopathy; LV torsion; Prognosis; Strain
Mesh:
Substances:
Year: 2021 PMID: 34852822 PMCID: PMC8638178 DOI: 10.1186/s12968-021-00829-x
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Illustration of the assessed strain parameters in long and short axis views. Long axis views (left: 4-chamber view) were used for the measurement of global longitudinal strain (GLS), three short axis views at apical, midventricular and basal level (right: apical short axis view) were used to evaluate global circumferential strain (GCS), global radial strain (GRS) and left ventricular (LV) torsion
Patient characteristics of the healthy—and dilated cardiomyopathy (DCM) group
| Healthy group (n = 70) | DCM group (n = 350) | p-value | |
|---|---|---|---|
| Age [years] | 51.9 ± 15.2 | 52.2 ± 15.2 | 0.87 |
| Male gender [n] | 46 (65.7%) | 259 (73.9%) | 0.16 |
| Weight [kg] | 75.9 ± 10.4 | 79.8 ± 15.7 | < 0.01 |
| Height [cm] | 174.4 ± 8.9 | 175.8 ± 9.3 | 0.26 |
| BMI [kg/m2] | 24.9 ± 3.0 | 25.8 ± 4.3 | < 0.05 |
| NYHA class [n] | |||
| I | 70 (100.0%) | 84 (24.0%) | < 0.001 |
| II | 0 | 152 (43.4%) | < 0.001 |
| III | 0 | 108 (30.9%) | < 0.001 |
| IV | 0 | 6 (1.7%) | < 0.001 |
| Cardiovascular risk factors [n] | |||
| Arterial hypertension | 0 | 154 (44.0%) | < 0.001 |
| Dyslipidemia | 0 | 89 (25.4%) | < 0.001 |
| Diabetes | 0 | 42 (12.0%) | < 0.001 |
| Smoker | 12 (17.1%) | 140 (40.0%) | < 0.001 |
| Family history of CAD | 0 | 77 (22.0%) | < 0.001 |
| Obesity | 4 (5.7%) | 52 (14.9%) | < 0.001 |
| Heart failure therapy | |||
| ACE inhibitor/ARB | 0 | 346 (98.9%) | < 0.001 |
| ß-Blocker | 0 | 300 (85.7%) | < 0.001 |
| Aldosterone receptor antagonist | 0 | 145 (41.4%) | < 0.001 |
| Loop diuretic | 0 | 169 (48.3%) | < 0.001 |
| Heart rate [/min] | 68.5 ± 10.1 | 71.4 ± 15.2 | 0.05 |
| Atrial fibrillation [n] | 0 | 55 (15.7%) | < 0.001 |
| Laboratory findings | |||
| Hemoglobine [g/dl] | 14.5 (13.5–15.4) | 14.3 (13.3–15.4) | 0.14 |
| Creatinine [mg/dl] | 0.9 (0.7–1.0) | 0.9 (0.8–1.1) | 0.10 |
| NT-pro BNP [ng/l] | 39.0 (24.0–61.0) | 373.0 (124.0–1797.0)† | < 0.001 |
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CAD coronary artery disease, NT-pro BNP N-terminal pro-hormone brain natriuretic peptide, NYHA New York Heart Association
†NT-pro BNP values of 110 patients missing
Comparison of CMR parameters including LV strain and rotational parameters between healthy—and DCM group
| Healthy group (n = 70) | DCM group (n = 350) | p-value | |
|---|---|---|---|
| LVEF [%] | 60.1 ± 5.1 | 36.4 ± 13.7 | < 0.001 |
| LVEDV [ml] | 168.0 ± 38.2 | 248.9 ± 94.4 | < 0.001 |
| LV mass [g] | 77.7 ± 20.9 | 147.3 ± 97.0 | < 0.001 |
| presence of LGE [n] | – | 134 (38.3%) | – |
| GLS [%] | − 17.5 ± 3.8 | − 9.9 ± 4.5 | < 0.001 |
| GCS [%] | − 19.1 ± 3.0 | − 9.4 ± 4.9 | < 0.001 |
| GRS [%] | 41.8 ± 14.6 | 23.5 ± 12.0 | < 0.001 |
| Apical rotation [°] | 6.1 ± 3.0 | 2.0 ± 4.1 | < 0.001 |
| Basal rotation [°] | − 4.8 ± 4.0 | − 2.5 ± 3.6 | < 0.001 |
| LV twist [°] | 10.3 ± 3.7 | 5.5 ± 3.0 | < 0.001 |
| LV torsion [°/cm] | 2.3 ± 0.9 | 1.2 ± 0.7 | < 0.001 |
| Normal directed rotation [n] | 62 (88.6%) | 191 (54.6%) | < 0.001 |
| Reversed apical rotation [n] | 1 (1.4%) | 98 (28.0%) | < 0.001 |
GCS global circumferential strain, GLS global longitudinal strain, GRS global radial strain, LVEDV left ventricular end-diastolic volume, LGE late gadolinium enhancement, LVEF left ventricular ejection fraction
Fig. 2Comparison of strain parameters: healthy control group vs. dilated cardiomyopathy (DCM) group. Box-whisker-plots for the comparison of different strain parameters including LV torsion between the healthy control and DCM group. a global longitudinal strain (GLS), b global circumferential strain (GCS), c global radial strain, (GRS) d LV torsion; * p < 0.001
Comparison of DCM patients without and with a primary endpoint
| No event (n = 291) | Primary endpoint (n = 59) | p-value | |
|---|---|---|---|
| Age [years] | 51.6 ± 15.2 | 55.2 ± 15.3 | 0.10 |
| Male gender [n] | 214 (73.5%) | 45 (76.3%) | 0.66 |
| Weight [kg] | 80.5 ± 16.0 | 76.4 ± 14.0 | 0.07 |
| Height [cm] | 176.0 ± 8.9 | 174.8 ± 11.1 | 0.44 |
| BMI [kg/m2] | 25.9 ± 4.4 | 24.9 ± 3.4 | < 0.05 |
| Heart rate [1/min] | 70.8 ± 15.2 | 74.4 ± 15.0 | 0.09 |
| Atrial fibrillation [n] | 46 (15.8%) | 11 (18.6%) | 0.58 |
| NYHA class [n] | |||
| I | 72 (24.7%) | 12 (20.3%) | 0.50 |
| II | 133 (45.7%) | 19 (32.2%) | 0.08 |
| III | 80 (27.5%) | 28 (47.5%) | < 0.01 |
| IV | 6 (2.1%) | 0 | – |
| Cardiovascular risk factors [n] | |||
| Arterial hypertension | 127 (43.6%) | 27 (45.8%) | 0.75 |
| Dyslipidemia | 76 (26.1%) | 13 (22.0%) | 0.51 |
| Diabetes | 31 (10.7%) | 11 (18.6%) | 0.14 |
| Smoker | 119 (40.9%) | 21 (35.6%) | 0.50 |
| Family history of CAD | 63 (21.6%) | 14 (23.7%) | 0.66 |
| Obesity | 47 (16.2%) | 5 (8.5%) | 0.08 |
| Heart failure therapy [n] | |||
| ACE inhibitor/ARB | 287 (98.6%) | 59 (100.0%) | 0.57 |
| ß-Blocker | 245 (84.2%) | 54 (91.5%) | 0.11 |
| Aldosterone receptor antagonist | 112 (38.5%) | 34 (57.6%) | < 0.01 |
| Loop diuretic | 128 (44.0%) | 42 (71.2%) | < 0.001 |
| Laboratory findings | |||
| Creatinine [mg/dl] | 0.9 (0.8–1.1) | 1.1 (0.9–1.3) | 0.45 |
| NT-pro BNP [ng/l]† | 275.0 (102.3–1229.8) | 1831 (411.3–4976.3) | < 0.05 |
| CMR parameters | |||
| LVEF [%] | 38.2 ± 13.2 | 27.1 ± 12.7 | < 0.001 |
| LVEDV [ml] | 239 ± 81 | 298 ± 133 | < 0.01 |
| LV mass [g] | 139 ± 50 | 189 ± 205 | 0.07 |
| Presence of LGE [n] | 97 (33.3%) | 37 (62.7%) | < 0.001 |
| GLS [%] | − 10.3 ± 4.5 | − 7.5 ± 3.7 | < 0.001 |
| GCS [%] | − 10.0 ± 4.9 | − 6.6 ± 3.6 | < 0.001 |
| GRS [%] | 24.7 ± 12.2 | 17.7 ± 9.4 | < 0.001 |
| Apical rotation [°] | 1.9 ± 4.2 | 2.3 ± 3.9 | 0.36 |
| Basal rotation [°] | − 2.5 ± 3.7 | − 2.3 ± 3.0 | 0.84 |
| LV twist [°] | 5.6 ± 3.1 | 5.0 ± 2.5 | 0.11 |
| LV torsion [°/cm] | 1.2 ± 0.7 | 1.0 ± 0.6 | < 0.05 |
| Normal directed rotation [n] | 159 (54.6%) | 32 (54.2%) | 0.98 |
| Reversed apical rotation [n] | 89 (27.1%) | 15 (25.4%) | 0.84 |
†NT-pro BNP values of 110 patients missing
Univariate survival analysis of the primary endpoint (Cox proportional-hazards regression)
| Primary endpoint | ||||
|---|---|---|---|---|
| HR | 95% CI | p-value | χ2 | |
| Age [years] | 1.02 | 1.00–1.04 | < 0.05 | 4.17 |
| NYHA | 1.49 | 1.04–2.14 | < 0.05 | 4.85 |
| LVEF [%] | 0.94 | 0.93–0.96 | < 0.001 | 35.85 |
| LVEDV [ml] | 1.01 | 1.00–1.01 | < 0.001 | 17.14 |
| lnNT-pro BNP [ng/l] | 1.52 | 1.32–1.75 | < 0.001 | 32.15 |
| LGE [n] | 3.05 | 1.79–5.22 | < 0.001 | 17.58 |
| GLS [%] | 1.22 | 1.14–1.31 | < 0.001 | 36.81 |
| GCS [%] | 1.23 | 1.14–1.32 | < 0.001 | 40.06 |
| GRS [%] | 0.94 | 0.91–0.97 | < 0.001 | 21.41 |
| LV twist [°] | 0.92 | 0.84–1.02 | 0.09 | 2.89 |
| LV torsion [°/cm] | 0.63 | 0.40–0.97 | < 0.05 | 4.90 |
| Reversed apical rotation [n] | 1.08 | 0.61–1.90 | 0.79 | 0.07 |
NT-pro BNP was log transformed (lnNT-pro BNP)
Multivariate survival analysis of the primary endpoint (Cox proportional-hazards regression)
| Primary endpoint | |||
|---|---|---|---|
| HR | 95% CI | p-value | |
| LVEF [%] | 1.00 | 0.95–1.05 | 0.90 |
| LVEDV [ml] | 1.00 | 1.00–1.01 | 0.50 |
| LGE [n] | 2.16 | 1.24–3.77 | < 0.05 |
| GLS [%] | 1.13 | 1.01–1.26 | < 0.05 |
| GCS [%] | 1.07 | 0.92–1.24 | 0.38 |
| GRS [%] | 0.99 | 0.96–1.03 | 0.71 |
| LV torsion [°/cm] | 1.26 | 0.74–2.13 | 0.40 |
Fig. 3Cox proportional-hazards model of the additional value of LV strain parameters. Strain parameters and late gadolinium enhancement (LGE) improve risk stratification significantly compared to LV ejection fraction (LVEF). p < 0.05
Fig. 4Kaplan–Meier survival analyses for the prediction of primary endpoint. Kaplan–Meier curves for LVEF (a) with cut-off value of ≤ 35%, the presence of LGE (b), GLS (c), GCS (d), GRS (e) and LV torsion (f)
Fig. 5Kaplan–Meier analysis of a CMR risk score in DCM patients. CMR risk score is based on different CMR (LVEF, LGE) and strain parameters (GLS, GCS, GRS, LV torsion) for the prediction of the primary endpoint (cut-off values as mentioned on the left): low risk (0–1p), intermediate risk (2–5p) and high risk (6p)